Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS p.Gln61Lys (p.Q61K)
(
ENST00000311936.8,
ENST00000693229.1,
ENST00000692768.1,
ENST00000557334.6,
ENST00000688940.1,
ENST00000256078.10,
ENST00000685328.1 )
KRAS p.Gln61Lys (p.Q61K) ( ENST00000693229.1, ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1 ) - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61K. One patient was a 61 year old female whose tumor was wildtype for BRAF and PIK3CA. This patient was treated with cetuximab, oxaliplatin, and 5FU, as a second line therapy, and experienced progressive disease 6 weeks following cetuximab administration; overall survival was 90 weeks. The other patient was a 65 year old female whose tumor was wildtype for PIK3CA. The patient was treated with cetuximab and irinotecan as a third line therapy, and experienced progressive disease 10 week following cetuximab. Both patients experienced progressive disease following treatment.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3872
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/910
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Chemotherapy,Cetuximab
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 20619739
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cetuximab | Resitance or Non-Reponse | true |
| Chemotherapy | Resitance or Non-Reponse | true |